Evidence Uncertainties Floors Celgene's Revlimid Once Again At NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE says lack of direct evidence comparing Celgene's Revlimid to a number of comparators means it currently cannot consider the drug to be cost effective.